More than 300 Medicines in are in the Research Pipeline for Autoimmune Diseases.
Today, more than 80 autoimmune diseases have been identified. Many more diseases are thought to be autoimmune but have not been scientifically been identified as such, and others are considered to be autoimmune-related conditions.
Although researchers do not know the exact cause of autoimmune diseases, progress is being made to better understand potential factors that may be involved. Scientists have discovered that autoimmune diseases tend to occur in members of the same family, suggesting a genetic component, and are more common in women than in men.
In autoimmune diseases, environmental elements, such as certain foods, chemicals or even physical trauma can trigger the immune system to attack the body, but often the cause for this reaction is not clear.
America’s biopharmaceutical research companies are responding to the needs of patients with autoimmune diseases by working to develop new innovative approaches to treatment. Today, biopharmaceutical companies have 311 medicines and vaccines for autoimmune diseases in clinical trials or awaiting review by the U.S. Food and Drug Administration (FDA). The medicines in development include:
76 for autoimmune types of arthritis, including juvenile idiopathic arthritis, which affects the majority of the nearly 300,000 children with arthritis, and rheumatoid arthritis, which affects 1.5 million people in the United States.
58 for in ammatory bowel disease, which includes Crohn’s disease and ulcerative colitis, and affects 1.6 million Americans.
39 for lupus, which affects an estimated 1.5 million Americans, with more than 16,000 new cases reported annually.
34 for type1diabetes,previously known as juvenile diabetes, with approximately 1.25 million American children and adults having the disease.
32 for multiple sclerosis, which is diagnosed most often between the ages of 20 and 50, and diagnosed at least two to three times more often in women than men
The 311 medicines in development for patients with autoimmune diseases use exciting new approaches aided by the growing scientific understanding of many of these diseases. In addition, medicines already approved to treat one autoimmune disease are being studied for applicability in treating additional diseases. Some of the medicines in the pipeline for autoimmune diseases include:
LUPUS - A monoclonal antibody medicine in development for the treatment of lupus which acts against a protein in the body that is thought to play a key role in the development of the disease. The protein helps regulate the activity of the immune system. By inhibiting the activity of the protein, the medicine is expected to halt the development of lupus.
PSORIASIS- Several monoclonal antibody medicines are in development for psoriasis that target a specific subunit of a receptor gene. The monoclonal antibodies bind to and neutralize the gene, which is thought to play a key role in autoimmune in ammatory processes that have been linked to many chronic autoimmune diseases, including psoriasis.
SJÖGREN’S SYNDROME- A monoclonal antibody medicine in development for the treatment of Sjögren’s syndrome binds to a protein in the body and prevents its interaction with stimulators on immune cells called activated T-cells. Preventing the interaction between the protein and the stimulator is thought to prevent increased immune cell responses associated with autoimmune diseases, such as Sjögren’s.
For a complete list of the 311 medicines in development, please visit: